These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19636556

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z.
    Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 8. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
    Deng M, Wang J, Chen Y, Zhang L, Liu D.
    Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, Mani S.
    Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
    [Abstract] [Full Text] [Related]

  • 12. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.
    Cell Cycle; 2011 Sep 01; 10(17):2959-66. PubMed ID: 21862872
    [Abstract] [Full Text] [Related]

  • 13. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 14. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
    Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.
    Cancer Res; 2013 Oct 01; 73(19):6013-23. PubMed ID: 23918797
    [Abstract] [Full Text] [Related]

  • 15. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
    Qin AC, Li Y, Zhou LN, Xing CG, Lu XS.
    Cell Physiol Biochem; 2019 Oct 01; 52(4):758-768. PubMed ID: 30933440
    [Abstract] [Full Text] [Related]

  • 16. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C, Liu VW, Chan DW, Yao KM, Ngan HY.
    Int J Gynecol Cancer; 2012 Jan 01; 22(1):15-22. PubMed ID: 22080879
    [Abstract] [Full Text] [Related]

  • 17. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y, Chen X, Luo Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun 01; 30(6):592-6. PubMed ID: 24909280
    [Abstract] [Full Text] [Related]

  • 18. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC.
    Mol Cancer Ther; 2007 Nov 01; 6(11):2843-57. PubMed ID: 18025271
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J.
    Mol Cancer Ther; 2011 May 01; 10(5):817-24. PubMed ID: 21383049
    [Abstract] [Full Text] [Related]

  • 20. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.